Issuance of Stock Acquisition Rights for Directors, Executive Officers and Employees
First written in FY2017-Q2. 20 of 23 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2026.
- FY2026AchievedAnnual report
「After vesting (shares) End of previous consolidated fiscal year 57,500 Exercise 9,000 Lapse 48,500 Balance unexercised —」
Of the stock options granted in 2019, 9,000 shares were exercised during the fiscal year, the remaining 48,500 shares lapsed, and there was no balance remaining unexercised. - FY2026-H1AdvancedAnnual report
「1 April 2025 to 30 September 2025 (Note) 9,000 63,406,879 3 10,870 3 12,872 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights during the interim accounting period increased the total number of issued shares by 9,000 and increased capital and the capital reserve by ¥3 million each. - FY2025AdvancedAnnual report
「1 April 2024 to 31 March 2025 (Note 1) 58,500 63,397,879 27 10,866 27 12,868 (Note 1) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights during the fiscal year increased the total number of issued shares by 58,500 and increased capital and the capital reserve by ¥27 million each. Of the rights granted in 2019, 57,500 shares remained unexercised as of the end of May 2025. - FY2025-H1AdvancedAnnual report
「1 April 2024 to 30 September 2024 (Note) 31,000 63,370,379 15 10,854 15 12,856 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights during the interim accounting period increased the total number of issued shares by 31,000 and increased capital and the capital reserve by ¥15 million each. - FY2024-Q3AdvancedAnnual report
「1 October 2023 to 31 December 2023 (Note 1) 35,000 63,251,379 17 10,792 17 12,794 (Note 1) Increase resulting from the exercise of stock acquisition rights. (Note 2) Between 1 January 2024 and 31 January 2024, the exercise of stock acquisition rights increased the total number of issued shares by 16,000 and increased capital and the capital reserve by ¥7 million each.」
The exercise of stock acquisition rights during the third quarter accounting period increased the total number of issued shares by 35,000 and increased capital and the capital reserve by ¥17 million each. In January 2024, before the filing date, 16,000 shares were exercised, increasing capital and the capital reserve by ¥7 million each. - FY2024-Q2AdvancedAnnual report
「1 July 2023 to 30 September 2023 (Note) 43,000 63,216,379 20 10,775 20 12,777 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights during the second quarter accounting period increased the total number of issued shares by 43,000 and increased capital and the capital reserve by ¥20 million each. - FY2024-Q1AdvancedAnnual report
「1 April 2023 to 30 June 2023 (Note 1) 87,000 63,173,379 40 10,754 40 12,756 (Note 1) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights during the first quarter accounting period increased the total number of issued shares by 87,000 and increased capital and the capital reserve by ¥40 million each. - FY2023AdvancedAnnual report
「The terms as of the end of the consolidated fiscal year (31 March 2023) are presented. … 12 June 2019 … Common shares: 226,000 … Exercise period: 1 July 2021 to 30 June 2025」
For stock acquisition rights for officers, executive officers and employees, the Company disclosed 226,000 unexercised shares remaining from the 2019 resolution, and 13,000 shares were exercised during the fiscal year. Restricted stock compensation also continued. - FY2022-Q3AdvancedAnnual report
「(Note) Between 1 January 2022 and 31 January 2022, the exercise of stock acquisition rights increased the total number of issued shares by 3,000 and increased capital and the capital reserve by ¥1 million each.」
There was no exercise of stock acquisition rights during the quarter accounting period, but exercises between 1 January and 31 January 2022, before the filing date, increased the total number of issued shares by 3,000 and increased capital and the capital reserve by ¥1 million each. - FY2022-Q2AdvancedAnnual report
「Increase resulting from the issuance of new shares as restricted stock compensation. Issue price ¥888 Amount included in capital ¥444 Allottees Directors of the Company (excluding outside directors) 4 people Executive officers who do not concurrently serve as directors of the Company 5 people 2. Increase resulting from the exercise of stock acquisition rights.」
The Company issued 18,983 shares as restricted stock compensation to 4 directors and 5 executive officers. During the quarter, the exercise of stock acquisition rights increased the number of shares by 27,000. - FY2022-Q1ReframedAnnual report
「1 April 2021 to 30 June 2021 (Note) 1 6,000 63,024,396 2 10,687 2 12,689 (Note) 1 Increase resulting from the exercise of stock acquisition rights. 2. The issuance of new shares as restricted stock compensation, with a payment date of 14 July 2021, increased the total number of issued shares by 18,983 and increased capital and the capital reserve by ¥8 million each.」
In addition to the increases in shares and capital resulting from the exercise of stock acquisition rights, the Company newly issued 18,983 shares as restricted stock compensation for directors and others, expanding the disclosed means of providing share-based compensation to officers and employees. - FY2020-Q3AdvancedAnnual report
「1 October 2019 to 31 December 2019 (Note) 7,000 63,018,396 3 10,684 3 12,686 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights during the third quarter accounting period increased the total number of issued shares by 7,000 and increased capital and the capital reserve by ¥3 million each. - FY2020-Q2AdvancedAnnual report
「Resolution date 12 June 2019 Categories and number of persons eligible for grants (people) Directors of the Company (excluding outside directors) 4 Executive officers of the Company 15 Employees of the Company 46 Number of stock acquisition rights ※ 3,160 (Note) 1 Class, description and number of shares underlying the stock acquisition rights (shares) ※ Common shares: 316,000 Exercise period for the stock acquisition rights ※ 1 July 2021 to 30 June 2025」
For the stock acquisition rights approved on 12 June 2019, the Company disclosed specific grant terms covering 4 directors, 15 executive officers and 46 employees, comprising 3,160 rights and 316,000 shares, with an exercise period from July 2021 to June 2025. - FY2019AdvancedAnnual report
「Resolution date 12 June 2019 Categories and number of persons eligible for grants (people) Directors of the Company (excluding outside directors), executive officers and employees Number of stock acquisition rights Up to 3,500 Class, description and number of shares underlying the stock acquisition rights (shares) Common shares; unit share size: 100 shares Up to 350,000 shares Exercise period for the stock acquisition rights 1 July 2021 to 30 June 2025」
The Company newly established stock acquisition rights for directors, executive officers and employees, capped at 3,500 rights and 350,000 shares, with an exercise period from July 2021 to June 2025. During the fiscal year, the exercise of stock acquisition rights increased the number of shares by 60,500. - FY2019-Q2AdvancedAnnual report
「Number of stock acquisition rights 3,260 (Note) 1 Class, description and number of shares underlying the stock acquisition rights (shares) ※ Common shares: 326,000 Exercise period for the stock acquisition rights ※ 1 July 2020 to 30 June 2024 1 July 2018 to 30 September 2018 (Note) 36,900 63,011,396 16 10,681 16 12,683 (Note) Increase resulting from the exercise of stock acquisition rights.」
The Company disclosed the terms of stock acquisition rights for directors, executive officers and employees, comprising 3,260 rights and 326,000 shares. Their exercise increased the total number of issued shares by 36,900 and increased capital and the capital reserve by ¥16 million each. - FY2019-Q1AdvancedAnnual report
「1 April 2018 to 30 June 2018 (Note) 1 23,600 62,974,496 13 10,665 13 12,667 (Note) 1 Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights during the quarter increased the total number of issued shares by 23,600 and increased capital and the capital reserve by ¥13 million each. - FY2018AdvancedAnnual report
「Resolution date 13 June 2018 Categories and number of persons eligible for grants (people) Directors of the Company (excluding outside directors), executive officers and employees Number of stock acquisition rights Up to 3,500 (Note) 1 Class, description and number of shares underlying the stock acquisition rights (shares) Common shares; unit share size: 100 shares Up to 350,000 shares Exercise period for the stock acquisition rights 1 July 2020 to 30 June 2024」
The Company disclosed new grant terms and an exercise period for stock acquisition rights for directors, executive officers and employees, with limits of 3,500 rights and 350,000 shares. - FY2018-Q3AdvancedAnnual report
「1 October 2017 to 31 December 2017 (Note) 1 136,900 62,888,096 80 10,615 80 12,617 (Note) 1 Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights increased the total number of issued shares by 136,900 during the third quarter accounting period, and increased capital and the capital reserve by ¥80 million each. - FY2018-Q2AdvancedAnnual report
「The stock acquisition rights issued during the second quarter accounting period are as follows. Number of stock acquisition rights 3,320 Number of shares underlying the stock acquisition rights 332,000 shares Exercise period for the stock acquisition rights 1 July 2019 to 30 June 2023 At the time of exercise, holders of the stock acquisition rights must be directors of the Company (excluding outside directors), executive officers or employees. 1 July 2017 to 30 September 2017 (Note) 23,900 62,751,196 13 10,534 13 12,536 (Note) Increase resulting from the exercise of stock acquisition rights.」
The Company issued 3,320 stock acquisition rights, representing 332,000 underlying shares, to directors, executive officers and employees. The exercise increased the total number of issued shares by 23,900 and increased capital and the capital reserve by ¥13 million each. - FY2018-Q1AdvancedAnnual report
「1 April 2017 to 30 June 2017 (Note) 7,000 62,727,296 3 10,521 3 12,523 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights increased the total number of issued shares by 7,000 during the first quarter accounting period, and increased capital and the capital reserve by ¥3 million each. - FY2017AdvancedAnnual report
「1 April 2016 to 31 March 2017 (Note) 33,600 62,720,296 17 10,518 17 12,520 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights during the fiscal year increased the total number of issued shares by 33,600 and increased capital and the capital reserve by ¥17 million each. - FY2017-Q3AdvancedAnnual report
「1 October 2016 to 31 December 2016 (Note) 20,600 62,713,296 11 10,514 11 12,516 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights increased the total number of issued shares by 20,600 during the third quarter accounting period, and increased capital and the capital reserve by ¥11 million each. - FY2017-Q2First statedAnnual report
「The stock acquisition rights issued during the second quarter accounting period are as follows. Number of stock acquisition rights 2,690 Number of shares underlying the stock acquisition rights 269,000 shares Exercise period for the stock acquisition rights 1 July 2018 to 30 June 2022 At the time of exercise, holders of the stock acquisition rights must be directors of the Company (excluding outside directors), executive officers or employees.」
The Company issued 2,690 stock acquisition rights, representing 269,000 underlying shares, to directors, executive officers and employees. The exercise period is from 1 July 2018 to 30 June 2022.